Camoteskimab is under clinical development by Apollo Therapeutics LLC and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Camoteskimab’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 08 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 08 Aug 2022 increased Camoteskimab’s LoA and PTSR for Relapsed Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Camoteskimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Camoteskimab overview

Camoteskimab (AEVI-007) is under development for adult onset Still’s disease (Rheumatoid arthritis) and relapsed or refractory multiple myeloma. It is administered intravenously as water for injection. It is a fully humanized monoclonal antibody acts by targeting interleukin 18. It was under development for the treatment chronic obstructive pulmonary disease (COPD).

Apollo Therapeutics LLC overview

Apollo Therapeutics LLC, is a biopharmaceutical company that engaged in advancing a pipeline of transformative therapeutic programs developing new treatment options for oncology indications, inflammatory disorders, and rare diseases. The company is headquartered in United States.

Quick View Camoteskimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Camoteskimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Musculoskeletal Disorders
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: Apollo Therapeutics
  • Originator: MedImmune
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.